Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Subsidiary Using Synthetic Biology Platform from Sloning

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biotech firm MorphoSys today announced an agreement between its recently acquired subsidiary Sloning BioTechnology and Pfizer for use of Sloning's synthetic biology technology.

Sloning will install its Slonomics platform at Pfizer's subsidiary Rinat Neuroscience in South San Francisco, Calif. Sloning will also provide training and use of the platform. Rinat has been using Sloning's services since 2009, Jaume Pons, chief scientific officer for Rinat, said in a statement.

Sloning will receive an upfront payment for an undisclosed amount in 2010, and licensing fees of the patent lifetime of the Slonomics technology, MorphoSys said.

Further financial and other terms of the deal were not disclosed.

MorphoSys acquired Sloning in October for €19 million ($25 million).

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.